Onco Actu du 14 juin 2018

	1.4 Biologie - Technos
Could Cancer Risk Claw CRISPR’s Potential? Some Balanced Perspectives [The Niche] Part of the challenge here is that people have been so enamored of gene editing that some folks hyped it a ton. Investors in gene editing-related companies have also pushed things into the over-exuberance zone too. This all of course set this technology up for a fall or multiple falls back toward rationale reality.
	3.1 Prévention - Tabac
Tobacco industry seeking to control anti-smuggling measures, say critics [The Guardian] UN protocol says mechanisms designed to counter illicit trade should not be delegated to industry, but monitors allege firms are involved.
	3.3 Prévention - Vaccins
Merck's Keytruda snags I-O's first cervical cancer nod to back up HPV fighter Gardasil [FiercePharma] In the first quarter, revenue for Merck’s Gardasil franchise grew 24%, trouncing analyst expectations, but the boost was largely thanks to a launch in China. In the U.S., Gardasil sales fell after a CDC-endorsed switch to a two-dose regimen rather than a three-dose regimen.
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases [Merck] “We look forward to working with the FDA on the review of this application for GARDASIL 9, which, if approved, would enable more people to have access to the vaccine.”
A dumpster fire of a study about HPV vaccination and female fertility, courtesy of Gayle Delong [Respectful Insolence] If there’s one thing about antivaccine activists (a.k.a. antivaxers), it’s that, no matter what, it’s always about the vaccines. Always. Whatever chronic health issue it might be, autism, autoimmune disease, diabetes, or whatever, to the antivaxer, it’s always the vaccines that did it. Always. I’ve just come across a new “study” by Gayle Delong supposedly implicating the HPV vaccine with female infertility that demonstrates this principle again through its sheer awfulness, as you will see.
	5. Traitements
The Search for Cancer Treatment That Is Personal and Useful [NY Times] By narrowing our definition of precision medicine too much, we almost narrowed our ambition to deliver precise, thoughtful therapy — or, at times, no therapy — to our patients. It would be a shame to view cancer through such narrow lenses again.
	5.1 Traitements - Pré-clinique
Blocking energy production could help treat lung cancer where chemotherapy has limited effect [Insstitute of Cancer Research] Scientists at the ICR, together with colleagues at the Institut Gustave Roussy, France, received funding from, the French National Cancer Plan, the INSERM-CNRS research institutions and the European Union, to identify a synthetically lethal relationship between ERCC1 and the energy production enzyme NAMPT in lung cancer.
	5.10 Traitements - Essais
Unreported clinical trial of the week: A prostate cancer vaccine in combination with flutamide (NCT00450463) [BMJ] This unreported trial was sponsored by the National Cancer Institute in collaboration with the National Institutes of Health Clinical Center. The study PI is Dr. Ravi A Madan of the National Cancer Institute. As of 13 June 2018, this trial is 47 days overdue to report. We hope the investigators will share the results of this trial soon.
	5.12 Immunothérapies
Older Melanoma Patients May Respond to Anti-PD1 Immunotherapy Better Than Younger Patients [AACR] In this multinational study, the researchers analyzed data from 538 patients with melanoma treated with the anti-PD1 therapy pembrolizumab (Keytruda) at eight different institutes worldwide. Of the patients, 238 were younger than 62 years.
	5.2 Pharma
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer [Seattle Genetics] Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment.
	5.3.4 Traitements - AMM (FDA, EMA,...)
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL) [Merck] KEYTRUDA is the First Anti-PD-1 Therapy Approved for Adult and Pediatric Patients with Refractory PMBCL or Who Have Relapsed After Two or More Prior Lines of Therapy.
FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery [Roche] Avastin is now approved for ten distinct uses across six different types of cancer in the United States.
FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL [FDA] Approval was based on data from 53 patients with relapsed or refractory PMBCL enrolled in a multicenter, open-label, single-arm trial, KEYNOTE‑170 (NCT02576990).
FDA approves bevacizumab in combination with chemotherapy for ovarian cancer [FDA] Approval was based on GOG-0218 (NCT00262847), a multicenter, randomized, double-blind, placebo-controlled, three-arm study evaluating the addition of bevacizumab to carboplatin and paclitaxel for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
	5.9 AACR
Q&A With Ari M. Melnick, MD, on Recent Advances in Lymphoma [Cancer Research Catalyst] The Inaugural AACR International Meeting "Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application" will be held June 22-26 in cooperation with the International Conference on Malignant Lymphoma (ICML).
	6. Lutte contre les cancers
I handed over my genetic data to the NIH. Here’s why you should, too [STAT] Many of us working on the All of Us Research Program have signed up as participants, including me. I trust our systems with my health data, knowing full well that no system is invulnerable. But to me, that small risk is vastly outweighed by the huge potential benefits from All of Us.
	6.1 Observation
Huge study shows cancer benefits, limitations of antiretroviral therapy for HIV [Stanford Medicine] Some 9 percent of the HIV-positive veterans followed in the study eventually contracted cancer of one type or another, as opposed to 6.8 percent of uninfected participants. Drilling down, the investigators observed substantially lower cancer rates among HIV-infected individuals who had achieved long-term viral suppression than among those who hadn't.
Race may be factor in who completes breast cancer chemotherapy [Reuters] After accounting for factors like age, insurance status and tumor size, white women were more than three times as likely to finish neoadjuvant chemotherapy as black, Hispanic and Asian women.